解析瑞士HIV队列研究中与SARS-CoV-2易感性降低相关的因素
基于瑞士HIV队列研究中6270名HIV感染者,分析2020年1月1日至2021年12月31日SARS-CoV-2 PCR检测、COVID-19住院和死亡数据,并检测大流行前(2019年)和大流行期间(2020年)生物样本库血浆中SARS-CoV-2和普通人类冠状病毒(HCoV)抗体。未发现HIV-1相关因素与SARS-CoV-2感染相关;大流行前高HCoV抗体与后续SARS-CoV-2感染风险降低及感染后更高抗体应答相关;吸烟对SARS-CoV-2感染风险显示强保护效应(调整OR 0.46,95%CI 0.38-0.56,P<0.001),既往吸烟者中亦存在,重度吸烟者最强。
要点
- 未发现HIV-1相关因素与SARS-CoV-2感染风险相关。
- 大流行前高HCoV抗体与后续SARS-CoV-2感染风险降低相关。
- 吸烟对SARS-CoV-2感染显示保护效应,调整OR 0.46(95%CI 0.38-0.56,P<0.001)。
核心结论
- 吸烟和HCoV抗体是两个独立保护因素,均影响呼吸道环境,凸显局部免疫微环境在调节SARS-CoV-2易感性中的重要性。
研究设计与样本
- 利用瑞士HIV队列研究中6270名HIV感染者的数据,分析2020年1月1日至2021年12月31日报告的SARS-CoV-2 PCR检测结果、COVID-19相关住院和死亡。
- 在大流行前(2019年)和大流行期间(2020年)生物样本库血浆样本中检测SARS-CoV-2和HCoV抗体,并与HIV阴性个体比较。
- 应用逻辑回归、条件逻辑回归和贝叶斯多变量回归识别HIV感染者中SARS-CoV-2感染决定因素和抗体应答。
主要发现
- 未发现HIV-1相关因素与SARS-CoV-2感染获得相关。
- 大流行前高HCoV抗体与后续SARS-CoV-2感染风险降低相关,并与感染时更高的SARS-CoV-2抗体应答相关。
- 吸烟对SARS-CoV-2感染风险显示强保护效应,调整OR 0.46(95%CI 0.38-0.56,P<0.001),既往吸烟者中亦出现,重度吸烟者最强。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Factors influencing susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain to be resolved. Using data from the Swiss HIV Cohort Study on 6270 people with human immunodeficiency virus (HIV) and serologic assessment for SARS-CoV-2 and circulating human coronavirus (HCoV) antibodies, we investigated the association of HIV-related and general parameters with SARS-CoV-2 infection. METHODS: We analyzed SARS-CoV-2 polymerase chain reaction test results, COVID-19-related hospitalizations, and deaths reported to the Swiss HIV Cohort Study between 1 January 2020 and 31 December 2021. Antibodies to SARS-CoV-2 and HCoVs were determined in prepandemic (2019) and pandemic (2020) biobanked plasma samples and compared with findings in HIV-negative individuals. We applied logistic regression, conditional logistic regression, and bayesian multivariate regression to identify determinants of SARS-CoV-2 infection and antibody responses to SARS-CoV-2 in people with HIV. RESULTS: No HIV-1-related factors were associated with SARS-CoV-2 acquisition. High prepandemic HCoV antibodies were associated with a lower risk of subsequent SARS-CoV-2 infection and with higher SARS-CoV-2 antibody responses on infection. We observed a robust protective effect of smoking on SARS-CoV-2 infection risk (adjusted odds ratio, 0.46 [95% confidence interval, .38-.56]; P < .001), which occurred even in previous smokers and was highest for heavy smokers. CONCLUSIONS: Our findings of 2 independent protective factors, smoking and HCoV antibodies, both affecting the respiratory environment, underscore the importance of the local immune milieu in regulating susceptibility to SARS-CoV-2.
引用
- Abela IA, Hauser A, Schwarzmüller M, et al. Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study. J Infect Dis. 2024. PMID: 38227786. doi:10.1093/infdis/jiae002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。